Visão geral da empresa Neos
1 escritórioLocalizações
Neos Therapeutics develops, manufactures, and commercializes branded products using our proprietary, extended-release drug delivery technology platform. We have used this technology to develop products for the treatment of attention deficit hyperactivity disorder (ADHD), including an extended-release orally disintegrating tablet. We are also using this technology to develop two additional product candidates:
Oral disintegrating tablets (ODT)
Oral suspension dosage forms.
The Formulations
In 2014 alone, 63.1 million prescriptions for medications with ADHD labeling, principally in extended-release formulations, were written in the United States. The vast majority of currently available dosage forms for ADHD are tablets and capsules. Our technology provides a plasma concentration-time profile that is consistent with once-daily dosing in an orally disintegrating tablet that allows the tablet to disintegrate in the mouth without water.
Oral disintegrating tablets (ODT)
Oral suspension dosage forms.
The Formulations
In 2014 alone, 63.1 million prescriptions for medications with ADHD labeling, principally in extended-release formulations, were written in the United States. The vast majority of currently available dosage forms for ADHD are tablets and capsules. Our technology provides a plasma concentration-time profile that is consistent with once-daily dosing in an orally disintegrating tablet that allows the tablet to disintegrate in the mouth without water.
